Ignite Creation Date:
2024-05-06 @ 6:54 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05828446
Status:
RECRUITING
Last Update Posted:
2023-05-11
First Post:
2023-01-19
Brief Title:
Improving Hepatocellular Carcinoma Screening
Sponsor:
Naik Vietti Violi
Organization:
University of Lausanne Hospitals
Study Overview
Official Title:
Prospective Comparison of Diagnostic Performance and Cost-effectiveness of US and Abbreviated MRI for Hepatocellular Carcinoma Screening
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AMRIK
Brief Summary:
This is a monocentric single blind interventional single arm study It is designed to compare the rates of detection of hepatocellular carcinoma HCC by ultrasound US used in clinical routine vs abbreviated magnetic resonance imaging AMRI The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and non-contrast AMRI
Interested and eligible patients will be enrolled and undergo HCC screening rounds including US - contrast-enhanced US clinical routine and screening MRI within the same week bi-annually
Interested and eligible patients will be enrolled and undergo HCC screening rounds including US - contrast-enhanced US clinical routine and screening MRI within the same week bi-annually
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None